• COINS and cross-border capital — U.S. restrictions are widely expected to pass, but investors and companies are already ...

Democrats will take control of Congress in January with a clear mandate to improve affordability, renewed animus toward the ...

Turning tumors into local immunotherapy factories is among the strategies highlighted in preclinical cell, gene, and mRNA ...

Alethio wants to lower platelet counts in essential thrombocythemia and shrink the malignant clone that drives their ...

FDA approved the first plasmid DNA-based immunotherapy in October, granting accelerated approval to Inovio’s Voceryq ...

Building better biological AI models requires more than simply generating more data. Four initiatives launched or expanded in ...

Caspian is developing an oral menin inhibitor to regenerate patients’ own pancreatic beta cells, with plans to begin testing ...

Washington spends enormous energy scrutinizing the policy positions of FDA commissioner nominees. But does it pay enough attention to whether they can ...

A single trading day offers limited evidence, but Friday’s sharp divergence between tech and large-cap biopharma stocks suggests the latter could ...

The political action committees of the 10 largest drugmakers by 2025 global pharmaceutical sales, along with PhRMA and BIO, directed nearly all their ...

Genetic studies continue to strengthen the case for targeting microglia in Alzheimer’s disease. The harder task is ...